Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.
We compared ciprofloxacin alone with ciprofloxacin plus rifampin (C + R) as a prophylactic antibacterial regimen for 40 patients with solid tumors treated with high-dose chemotherapy and autologous stem cell transplantation support. No differences were found between groups in the time elapsed to the onset of fever, incidence of febrile episodes, amphotericin B use, and length of hospital stay. However, C + R combination prophylaxis significantly reduced the incidence of gram-positive bacteremia (five versus zero episodes) but was associated with a higher incidence of drug-related side effects.
Hidalgo
M
M
Division of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Hornedo
J
J
Lumbreras
C
C
Trigo
J M
JM
Gómez
C
C
Perea
S
S
Ruiz
A
A
Hitt
R
R
Cortés-Funes
H
H
D000328:Adult; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000209:etiology / Q000517:prevention & control; D016908:Gram-Positive Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy; D009503:Neutropenia / Q000139:chemically induced*; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D002939:Ciprofloxacin; D012293:Rifampin